Science4Data Article Insights

https://www.axios.com/regeneron-starts-human-trials-coronavirus-antibody-drugs-fba3cb23-6cb0-4b0d-9dec-4c1133473b15.html

Regeneron starts human trials for coronavirus antibody drugs

2020-06-11 14:36:10, Bob Herman, Axios

Content Categorization
/Business & Industrial/Pharmaceuticals & Biotech
/Health/Pharmacy/Drugs & Medications

Word Count:
190

Words/Sentence:
27

Reading Time:
1.90 min

Reading Quality:
Advanced

Readability:
16th or higher

Media Sentiment
Proprietary sentiment analysis on both the headline and body text of the article. Sentiment scores range from -1 (very negative sentiment) to 1 (very positive sentiment).
RCS Analysis
Relative scoring for Risk, Crisis, and Security language within the article.
Risk Score
Scoring based on the composite risk, security and crisis language within an article compared to a baseline of historic analysis across thousands of diverse articles.
PESTEL Scope
Analysis of article orientation across the PESTEL macro-environmental analysis framework. Learn more about PESTEL.
Entity Word Cloud
Key people, places, organizations and events referenced in the article, weighted by frequency and colored based on contextual sentiment.
Auto Summary
Condensing key features of the article based on salience analysis. Helpful for “gisting” the article in a time crunch.

Regeneron Pharmaceuticals is testing a new coronavirus antibody drug in humans as part of a federally funded, wide-ranging, placebo-controlled clinical trial.

Eli Lilly similarly is testing its own coronavirus antibody treatment and hopes to get emergency authorization by the fall, Reuters reported.

Between the lines: Regeneron has had some success with this idea of combining antibodies into one treatment as a way to ward off invading diseases – most recently with a treatment for the Ebola virus.

Details: Regeneron is testing its "antibody cocktail" in four patient groups, according to the company's announcement:"Hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as health care workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate)."

We're several months away from knowing whether these treatments are safe and effective against the virus and disease.

Keywords
Biomedical Advanced Research and Development Authority (BARDA), Pharmaceutical companies, COVID-19, Pharmaceutical industry, Coronavirus, COVID-19 treatments, Infectious disease, Big Pharma

Interested in Learning More?

Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.